Nicotinamide mononucleotide alleviate ischemia-reperfusion injury after lung transplantation

Lung ischemia-reperfusion injury (LIRI) is associated with a variety of postoperative complications and affects patient prognosis. Nicotinamide mononucleotide (NMN) has attracted much attention due to its potential role in cellular energy metabolism and antioxidant properties. Exploring the mitigating role of NMN in ischemia-reperfusion injury after lung transplantation is crucial for improving lung transplantation success and patient quality of life.The cold ischemia-reperfusion (CIR) model with BEAS-2B cells in vitro was used to simulate the lung transplantation.